Skip to Main content Skip to Navigation
Journal articles

Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population

Marthe Plaquevent 1, 2, 3 Florence Tétart 1, 2, 3 Laurence Fardet 4 Saskia Ingen-Housz-Oro 4 Laurence Valeyrie-Allanore 4 Philippe Bernard 5 Vivien Hebert 1, 2, 3 Aude Roussel 6 Martine Avenel-Audran 7 Guillaume Chaby 8 Michel D’incan 9 Marie-Christine Ferrier-Le-Bouedec 9 Sophie Duvert-Lehembre 10 Catherine Picard-Dahan 11, 12 Géraldine Jeudy 13 Evelyne Collet 13 Bruno Labeille 14, 15 Cécile Morice 16 Marie-Aleth Richard 17 Isabelle Bourgault-Villada 18 Noémie Litrowski 19 Corina Bara 20 Emmanuel Mahé 21 Catherine Prost-Squarcioni 22 Marina Alexandre 22 Gaëlle Quéreux 23 Claire Bernier 23 Angèle Soria 24 Domitille Thomas-Beaulieu 25 Christine Pauwels 25 Olivier Dereure 26 Jacques Benichou 27, 28 Pascal Joly 1, 2, 3
Abstract : Dipeptidyl peptidase-4 inhibitors have been suspected to induce bullous pemphigoid (BP). The objective of this study was to compare the observed frequency of gliptin intake in a large sample of 1,787 BP patients diagnosed between 2012 and 2015 in France, with the expected frequency after indirect age standardization on 225,412 individuals extracted from the database of the National Healthcare Insurance Agency. The secondary objective was to assess the clinical characteristics and the course of gliptin-associated BP, depending on whether gliptin was continued or stopped. The observed frequencies of intake of the whole gliptin class and that of vildagliptin in the BP population were higher than those in the general population after age standardization (whole gliptin class: 6.0%; 95% confidence interval = 4.9-7.1% vs. 3.6%, observed-to-expected drug intake ratio = 1.7; 95% confidence interval = 1.4-2.0; P < 0.0001; vildagliptin = 3.3%; 95% confidence interval = 2.5-4.1% vs. 0.7%, ratio = 4.4; 95% confidence interval = 3.5-5.7; P < 0.0001). The association of any gliptin+metformin was also higher than in the general population, ratio = 1.8 (95% confidence interval = 1.3-2.4; P < 0.0001). Gliptin-associated BP had no specific clinical characteristics. Gliptin was stopped in 48 (45.3%) cases. Median duration to achieve disease control, rate, and delay of relapse were not different whether gliptin was stopped or continued. This study strongly supports the association between gliptin intake, particularly vildagliptin, and the onset of BP.
Document type :
Journal articles
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-02090290
Contributor : Accord Elsevier Ccsd Connect in order to contact the contributor
Submitted on : Friday, October 22, 2021 - 3:15:44 PM
Last modification on : Tuesday, December 21, 2021 - 2:50:06 PM

File

S0022202X18329233.pdf
Files produced by the author(s)

Licence


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Identifiers

Citation

Marthe Plaquevent, Florence Tétart, Laurence Fardet, Saskia Ingen-Housz-Oro, Laurence Valeyrie-Allanore, et al.. Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population. Journal of Investigative Dermatology, Nature Publishing Group, 2019, 139 (4), pp.835-841. ⟨10.1016/j.jid.2018.10.045⟩. ⟨hal-02090290⟩

Share

Metrics

Les métriques sont temporairement indisponibles